Inventor · disambiguated record
Rebecca Louise Davie
Also filed as: DAVIE REBECCA LOUISE
14 granted patents·9 pending applications·67 citations·filing 2012–2024
90Inventor score
Top patents by PatentIndex Score
23 records- 0191US10364238B2N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2015·Granted Jul 30, 2019·8 cites·16 claims
- 0289US10781181B2N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2015·Granted Sep 22, 2020·6 cites·36 claims
- 0389US10611758B2N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2019·Granted Apr 7, 2020·4 cites·1 claims
- 0488US9533987B2Heterocyclic derivatesKALVISTA PHARMACEUTICALS LTD·Filed 2014·Granted Jan 3, 2017·19 cites·27 claims
- 0587US2025074903A1N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein InhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 0685US9670157B2Benzylamine derivativesKALVISTA PHARMACEUTICALS LTD·Filed 2014·Granted Jun 6, 2017·13 cites·30 claims
- 0784US9738641B2Bicyclic inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2014·Granted Aug 22, 2017·13 cites·29 claims
- 0879US9834513B2Benzylamine derivativesKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Dec 5, 2017·4 cites·26 claims
- 0977US2022289729A1N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein InhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1076US11001578B2N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2019·Granted May 11, 2021·0 cites·30 claims
- 1175US11084809B2N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2020·Granted Aug 10, 2021·0 cites·15 claims
- 1272US11198691B2N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2020·Granted Dec 14, 2021·0 cites·24 claims
- 1369US2023250080A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 1464US11613527B2Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2021·Granted Mar 28, 2023·0 cites·46 claims
- 1563US2022002275A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1656US11180484B2Pyrazole derivatives as plasma kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Nov 23, 2021·0 cites·4 claims
- 1754US2024059691A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1853US2024327412A1Factor xiia inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1948US2022289727A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 2046US9051249B2Benzylamine derivatives as inhibitors of plasma kallikreinEVANS DAVID MICHAEL·Filed 2012·Granted Jun 9, 2015·0 cites·17 claims
- 2143US2022298138A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 2243US2022298141A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 2341US9234000B2Benzylamine derivatives as inhibitors of plasma kallikreinKALVISTA PHARMACEUTICALS LTD·Filed 2015·Granted Jan 12, 2016·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Rebecca Louise Davie files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →